Literature DB >> 12587962

Hyperuricemia as a prognostic factor in pulmonary arterial hypertension.

D Bendayan1, D Shitrit, M Ygla, M Huerta, G Fink, M R Kramer.   

Abstract

Pulmonary arterial hypertension is a malignant disease with a median survival of 3 years. Uric acid levels are elevated in severe heart failure and in states of hypoxemia. Early data suggest a correlation between hyperuricemia and severe pulmonary arterial hypertension. We studied 29 patients with pulmonary arterial hypertension diagnosed and treated between 1998 and 2001. Clinical characteristics (6 min walk test and New York Heart Association class) and hemodynamic parameters (pulmonary artery pressure, pulmonary vascular resistance and cardiac output) were evaluated and correlated to uric acid level in a retrospective study. Uric acid levels correlated positively with New York Heart Association class (r=0.66, P<0.001) and negatively with 6 min walk test (r=-0.35, P=0.03). Uric acid levels were higher in patients who died than in patients who survived at the end ofthe follow-up period (8.8 vs. 5.7 mg/dl, P=0.001). This study shows that uric acid levels are elevated in severe pulmonary arterial hypertension and can be used as a prognostic marker of disease severity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12587962     DOI: 10.1053/rmed.2003.1440

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  23 in total

Review 1.  Right ventricular failure: a novel era of targeted therapy.

Authors:  Dipanjan Banerjee; Francois Haddad; Roham T Zamanian; Jayan Nagendran
Journal:  Curr Heart Fail Rep       Date:  2010-12

2.  Severe pulmonary arterial hypertension due to Angiostrongylosus vasorum in a dog.

Authors:  Audrey P Nicolle; Valérie Chetboul; Dominique Tessier-Vetzel; Carolina Carlos Sampedrano; Edouard Aletti; Jean-Louis Pouchelon
Journal:  Can Vet J       Date:  2006-08       Impact factor: 1.008

Review 3.  Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.

Authors:  Jennifer L Snow; Steven M Kawut
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

4.  Metabolomics of exercise pulmonary hypertension are intermediate between controls and patients with pulmonary arterial hypertension.

Authors:  Jason L Sanders; Yuchi Han; Mariana F Urbina; David M Systrom; Aaron B Waxman
Journal:  Pulm Circ       Date:  2019-10-30       Impact factor: 3.017

5.  CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival.

Authors:  Gustavo A Heresi; Metin Aytekin; Jennie Newman; Raed A Dweik
Journal:  Lung       Date:  2010-02-26       Impact factor: 2.584

6.  Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study.

Authors:  Theodoros Dimitroulas; Georgios Giannakoulas; Hariklia Dimitroula; Tilemahos Sfetsios; Despina Parcharidou; Haralambos Karvounis; Loukas Settas
Journal:  Rheumatol Int       Date:  2010-07-25       Impact factor: 2.631

7.  Mutations in the mitochondrial seryl-tRNA synthetase cause hyperuricemia, pulmonary hypertension, renal failure in infancy and alkalosis, HUPRA syndrome.

Authors:  Ruth Belostotsky; Efrat Ben-Shalom; Choni Rinat; Rachel Becker-Cohen; Sofia Feinstein; Sharon Zeligson; Reeval Segel; Orly Elpeleg; Suheir Nassar; Yaacov Frishberg
Journal:  Am J Hum Genet       Date:  2011-01-20       Impact factor: 11.025

8.  Oxidative stress in Mexicans with diffuse cutaneous systemic sclerosis.

Authors:  M P Cruz-Domínguez; D H Montes-Cortes; I M Olivares-Corichi; O Vera-Lastra; G Medina; L J Jara
Journal:  Rheumatol Int       Date:  2013-03-02       Impact factor: 2.631

9.  Relationship between serum uric acid levels and ventricular function in patients with idiopathic pulmonary hypertension.

Authors:  Chun-Yan Zhang; Long-Le Ma; Le-Xin Wang
Journal:  Exp Clin Cardiol       Date:  2013

10.  Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells.

Authors:  Sergey Zharikov; Karina Krotova; Hanbo Hu; Chris Baylis; Richard J Johnson; Edward R Block; Jawaharlal Patel
Journal:  Am J Physiol Cell Physiol       Date:  2008-09-10       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.